Haines John R

SEC source: 0001493152-26-016833 · ownership.xml · derivative · entry 3

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,641 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.

F4 · derivative.exercise_date: On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2026. The Class a common stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.

F4 · derivative.expiration_date: On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2026. The Class a common stock into which such vested RSUs converted on April 13, 2026 is reported in Table I on this Form 4.

SEC source: 0001493152-26-016833 · ownership.xml · nonDerivative · entry 2

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,179

F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2026.

SEC source: 0001493152-26-016833 · ownership.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,762

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.

F1 · shares: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2026. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.

SEC source: 0001641172-25-004822 · ownership.xml · derivative · entry 3

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,641

Underlying: Class A Common Stock · 1,641 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.

F4 · derivative.exercise_date: On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2025. The Class a common stock into which such vested RSUs converted on April 13, 2025 is reported in Table I on this Form 4.

F4 · derivative.expiration_date: On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2025. The Class a common stock into which such vested RSUs converted on April 13, 2025 is reported in Table I on this Form 4.

SEC source: 0001641172-25-004822 · ownership.xml · nonDerivative · entry 2

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,121

F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on April 13, 2025.

SEC source: 0001641172-25-004822 · ownership.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,698

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.

F1 · shares: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On April 13, 2022, the reporting person was granted 6,562 RSUs, 25% of which vested on April 13, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 28, 2022.

SEC source: 0001493152-25-007596 · ownership.xml · derivative · entry 3

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Celularity Inc. Class A Common Stock.

F4 · derivative.exercise_date: On February 17, 2023, the reporting person was granted 20,000 RSUs, which vested on February 17, 2025. The Class a common stock into which such vested RSUs converted on February 17, 2025 is reported in Table I on this Form 4.

F4 · derivative.expiration_date: On February 17, 2023, the reporting person was granted 20,000 RSUs, which vested on February 17, 2025. The Class a common stock into which such vested RSUs converted on February 17, 2025 is reported in Table I on this Form 4.

SEC source: 0001493152-25-007596 · ownership.xml · nonDerivative · entry 2

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,057

F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on February 17, 2025.

SEC source: 0001493152-25-007596 · ownership.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On February 17, 2023, the reporting person was granted 20,000 RSUs, which vested on February 17, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on February 22, 2023.

F1 · shares: Represents the conversion upon vesting of restricted stock units (RSUs) into Class A common stock. On February 17, 2023, the reporting person was granted 20,000 RSUs, which vested on February 17, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on February 22, 2023.

SEC source: 0001493152-24-014946 · ownership.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,373

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.

F2 · balance_after: Includes 37,310 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting.

F3 · balance_after: On February 29, 2024, the Issuer effected a 1-for-10 reverse stock split (the "Reverse Stock Split") on its Common Stock. The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0001493152-24-007475 · ownership.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 389,497

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.

F2 · balance_after: Includes 378,863 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting.

SEC source: 0001493152-24-007475 · ownership.xml · derivative · entry 2

Haines John R · CIK 0001867686 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,014

Underlying: Class A Common Stock · 216,014 shares

Expires 2034-02-15

F3 · derivative.exercise_date: The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date.

SEC source: 0000899243-23-011339 · doc4.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 459,847

F1 · shares: Represents shares withheld by the Issuer to satisfy its tax withholding obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.

F2 · balance_after: Includes 449,213 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting.

SEC source: 0000899243-23-005921 · doc4.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · Senior Exec Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 465,617

F1 · price: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs is subject to time-based vesting over a two-year period, with 50% vesting on the one-year anniversary of the grant date, and the remainder vesting on the two-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.

F2 · balance_after: These shares represent 465,617 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting.

SEC source: 0000899243-22-015913 · doc4.xml · derivative · entry 2

Haines John R · CIK 0001867686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,401

Underlying: Class A Common Stock · 192,401 shares

Expires 2032-04-13

F2 · derivative.exercise_date: This option shall vest and become exercisable over a four-year period, with 25% of the option vesting on the one-year anniversary of the grant date, and the remainder vesting in equal monthly installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.

SEC source: 0000899243-22-015913 · doc4.xml · nonDerivative · entry 1

Haines John R · CIK 0001867686 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,617

F1 · price: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs is subject to time-based vesting over a four-year period, with 25% vesting on the one-year anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that vested in full on the four-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.

SEC source: 0001213900-21-047744 · ownership.xml · derivative · entry 1

Haines John R · CIK 0001867686 · Chief Ops & Admin Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,297

Underlying: Class A Common Stock · 384,297 shares

Expires 2031-09-09

F1 · derivative.exercise_date: This option shall vest and become exercisable as follows: 50% is fully-vested as of the grant date; 50% is subject to time-based vesting over a four-year period from the July 16, 2021 closing of the business combination, with 25% of this tranche vesting on the one-year anniversary of the closing (July 16, 2022), and the remainder vesting monthly thereafter so that vested in full on the four-year anniversary of the business combination closing date, and subject to the Reporting Person's continuous service on each vesting date.

SEC source: 0001209191-21-047515 · doc4.xml · derivative · entry 6

Haines John R · CIK 0001867686 · Chief Operations & Admin Offcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,297

Underlying: Class A Common Stock · 384,297 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001209191-21-047515 · doc4.xml · derivative · entry 5

Haines John R · CIK 0001867686 · Chief Operations & Admin Offcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,830

Underlying: Class A Common Stock · 204,830 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001209191-21-047515 · doc4.xml · derivative · entry 4

Haines John R · CIK 0001867686 · Chief Operations & Admin Offcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,138

Underlying: Class A Common Stock · 61,138 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F4 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, December 15, 2019, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.

SEC source: 0001209191-21-047515 · doc4.xml · derivative · entry 3

Haines John R · CIK 0001867686 · Chief Operations & Admin Offcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,138

Underlying: Class A Common Stock · 61,138 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F1 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001209191-21-047515 · doc4.xml · derivative · entry 2

Haines John R · CIK 0001867686 · Chief Operations & Admin Offcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,276

Underlying: Class A Common Stock · 122,276 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F3 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 28, 2018, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.

SEC source: 0001209191-21-047515 · doc4.xml · derivative · entry 1

Haines John R · CIK 0001867686 · Chief Operations & Admin Offcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,607

Underlying: Class A Common Stock · 102,607 shares

Expires 2031-07-16

F2 · price: Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."

F1 · derivative.exercise_date: This option is fully vested and exercisable.